Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
The price is quite high at around 30 times estimated 2018 earnings and J&J is paying a lot while R&D is not even included, just a substantial minority stake in…
J&J CEO Alex Gorsky stated adding Actelion portfolio to the Janssen business is a unique opportunity to expand with leading differentiated medicines in PAH
J&J outmaneuvered Sanofi in the $30 billion battle for Actelion, securing a leading franchise in pulmonary arterial hypertension medicines that diversifies its…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Johnson & Johnson acquired Actelion for approximately $30 billion ($280 per share in cash) in an all-cash tender offer, gaining the world's leading pulmonary arterial hypertension franchise including Opsumit, Uptravi, and Tracleer. Actelion's drug discovery and early-stage R&D were spun out into a new Swiss company (Idorsia) with CHF 1 billion in capital.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Actelion Ltd (this deal) | 2017 | $30.0B | 90 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
| Johnson & Johnson / Genmab A/S | 2012 | $3.0B | 77 |
← Browse all deals · How we score deals
More: 2017 deals · Johnson & Johnson deals · Cardiovascular deals